Eradication of B cell tumors by minicircle DNA-mediated CD20/CD3 bispecific antibody production
文献类型：会议论文
| 作者 | Xiao-Juan Pang; Fei Ma; Pei-Fa Zhang; Jing Zhang; Yu-Jian Zhong; Yi Hou; Tian-Yan Wang; Gang Zheng; Cheng-Yi He; Zhi-Ying Chen |
| 出版日期 | 2015 |
| 会议名称 | New horizons in cancer research |
| 会议地点 | 中国上海 |
| 英文摘要 | Host immune response to viral vectors and sustained transgene expression of non-viral vectors are major challenges in gene-associated therapy. To overcome these obstacles, we used minicircle (MC) DNA vectorsthat only contain a minimal expression cassette for the stable and persistent expression of target gene. The use of bispecific antibody (BsAb) is an attractive and specific approach to cancer therapy,especially to human B cell lymphoma. We have constructed a MC-DNA vector that expressed a BsAb capable of binding CD20on B lymphoma cells and CD3 on cytotoxic T lymphocytes. Flow cytometry showed that the CD20/CD3 BsAb specifically bond to both the CD20 and CD3-positive cells simultaneously. In vitro, the CD20/CD3 could induce the lysis of cultured Raji cells in the presence of dendritic cell activated and cytokine induced killed (D-CIK) cells. In vivo, CD20/CD3 BsAb was continuously expressed in the serum via hydrodynamic technique. Meanwhile, we combinated D-CIK cells with CD20/CD3 BsAb to eradicate the established tumors in the nonobese diabetic-severse combined immunodeficiencydisease (NOD-SCID) mice. Compared to other groups, combination therapy significantly prolonged the survival time of the mice. This study demonstrates that MCs have the potential to serve as powerful vectors in immunotherapy of human cancer. |
| 收录类别 | 其他 |
| 语种 | 英语 |
| 源URL | [http://ir.siat.ac.cn:8080/handle/172644/7489]  |
| 专题 | 深圳先进技术研究院_医药所 |
| 作者单位 | 2015 |
| 推荐引用方式 GB/T 7714 | Xiao-Juan Pang,Fei Ma,Pei-Fa Zhang,et al. Eradication of B cell tumors by minicircle DNA-mediated CD20/CD3 bispecific antibody production[C]. 见:New horizons in cancer research. 中国上海. |
入库方式： OAI收割
来源：深圳先进技术研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。